Alpha Teknova, Inc. reports recurring financial and operating updates as a life-sciences reagent manufacturer serving therapy, vaccine and molecular-diagnostics workflows. The company organizes revenue around Lab Essentials and Clinical Solutions, with products that include agar plates, microbial culture and cryopreservation media, buffers, molecular biology reagents and water used across research-use and GMP production settings.
Company news commonly covers quarterly and annual results, revenue guidance, segment performance, Clinical Solutions customer activity, cash use, borrowings and free cash flow. Updates also describe Teknova’s modular manufacturing platform and its role in supplying foundational reagents for genomics, synthetic biology, molecular diagnostics and emerging therapeutic modalities.
Alpha Teknova (Nasdaq: TKNO) will report third-quarter 2026 financial results on November 4, 2026, after the market closes. The results cover the quarter ended September 30, 2026. A webcast and conference call will begin at 6:00 p.m. Eastern Time that day, with a replay available on the company’s website approximately two hours after the event.
Alpha Teknova (Nasdaq: TKNO) priced an underwritten public offering of its common stock expected to raise $40 million in gross proceeds.
The offering comprises 8,000,000 shares at $5.00 each, all sold by Teknova. Expected gross proceeds exclude underwriting discounts, commissions and offering expenses. Underwriters have a 30-day option to purchase up to 1,200,000 additional shares. The company expects closing on or about October 22, 2026, subject to customary closing conditions. Teknova intends to use net proceeds for general corporate purposes, potentially including repayment of outstanding debt obligations.
Alpha Teknova (Nasdaq: TKNO) has commenced an underwritten public offering of common stock, with all shares to be sold by Teknova.
The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered. Completion, size and terms remain uncertain and subject to market and other conditions. Teknova intends to use net proceeds for general corporate purposes, potentially including repayment of outstanding debt obligations, and may invest in complementary businesses, products or technologies; no such commitments or arrangements currently exist. TD Cowen and William Blair are joint book-running managers.
Teknova (Nasdaq: TKNO) announced preliminary, unaudited third-quarter 2026 financial results, estimating revenue growth of 19% to 21% from a year earlier.
For the three months ended September 30, 2026, estimated revenue was $12.5 million to $12.7 million. Estimated gross margin was 36.0% to 38.0%, up 500–700 basis points year over year. Adjusted EBITDA, a measure of earnings excluding certain expenses, was estimated at negative $1.2 million to negative $1 million, an improvement of at least 25% year over year. Estimated net loss was $3.694 million to $3.494 million. Cash and short-term investments were estimated at $16.6 million as of September 30.
The results accompanied a preliminary prospectus supplement filing. Estimates remain subject to financial closing and quarterly review, could change materially, and have not been audited or reviewed by the independent accounting firm.
Teknova (TKNO) and Pluristyx announced that Pluristyx is completing a Drug Master File for the PluriFreeze cryopreservation system for FDA submission. The Type II file documents chemistry, manufacturing and controls for the system, which protects cells during storage and freezing.
Teknova is the exclusive manufacturer and distributor in the United States and Canada and contributed manufacturing and quality content to the file. Developers using PluriFreeze in preclinical work can request authorization from Pluristyx to reference the file in applications for clinical trials and biologic product licenses. The companies describe the documentation as supporting progression into clinical manufacturing.
Alpha Teknova (TKNO) launched its proprietary Fill-Tek™ Dispensing System/b) on September 16, 2026 to expand custom single-use bag manufacturing without adding turnaround time.Fill-Tek dispenses an entire custom reagent order as a single lot across multiple bag sizes and quantities, removing per-bag-size minimums tied to fixed manifold designs. Customers can configure bags from 250 mL to 200 L, tailoring fill volumes, QC sample plans, testing requirements, and connectors. The system uses validated aseptic welds and runs in ISO-classified cleanrooms under an ISO 13485:2016 quality system, and is available for RUO, RUO+, and GMP grades with batch volumes from 8–2,000 liters. Orders can be placed via Teknova’s Build-Tek™ Custom Configurator, email, or phone.
Teknova (Nasdaq: TKNO) reported second quarter 2026 revenue of $12.2 million, an 18% increase from $10.3 million a year earlier, driven by growth in Lab Essentials and Clinical Solutions. Lab Essentials revenue rose to $9.2 million and Clinical Solutions to $2.4 million, both up 18% year over year.
Gross profit reached $4.9 million with gross margin of 40.1%, up from 38.7%. Operating expenses were $7.8 million, leading to a net loss of $3.2 million, or -$0.06 per share, modestly better than the prior-year loss of $3.6 million. Adjusted EBITDA was -$0.7 million.
Teknova reported total cash and short-term investments of $17.4 million and total borrowings of $13.2 million at June 30, 2026. Free Cash Outflow improved to $0.6 million from $2.3 million. Based on these results, the company raised its 2026 revenue outlook to $45–47 million and now expects Free Cash Outflow of less than $8 million. Teknova also launched Build-Tek™, an AI-powered custom configurator for complex reagent products.
Teknova (Nasdaq: TKNO) launched Build-Tek™, an AI-powered custom order configurator that lets therapeutic and diagnostic developers design complex custom reagents and submit quote requests in minutes. The system, beta-tested since June 2026, now spans Teknova’s full portfolio of products, container formats, and manufacturing grades.
Build-Tek’s interactive assistant guides users through product type, formulation, containers, QC testing, timelines, and add-on services, enabling multiple custom products per session. Teknova’s technical team reviews each request, typically returning a quote in two to three business days, with volumes ranging from 8 to 2,000 liters across RUO, RUO+, and GMP grades.
Alpha Teknova (Nasdaq: TKNO) will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, after the market close. The company will host a webcast and conference call the same day at 6:00 p.m. Eastern Time, accessible via the Investor Relations section of its website, with a replay available about two hours later.
Teknova (Nasdaq: TKNO) reported Q1 2026 revenue of $11.1 million, up 13% year-over-year, driven by Clinical Solutions growth. Gross profit was $3.8 million and gross margin rose to 34.2%. Net loss was $4.6 million (negative $0.08 per diluted share). Adjusted EBITDA improved to negative $2.0 million. Cash and short-term investments were $17.8 million with total borrowings of $13.2 million. The company reaffirmed 2026 revenue guidance of $42–44 million and expects full-year Free Cash Outflow of less than $10 million.